Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 2.58. At the close of trading, the stock’s price was $15.26, to imply a decrease of -0.26% or -$0.04 in intraday trading. The CRBP share’s 52-week high remains $61.90, putting it -305.64% down since that peak but still an impressive 67.63% since price per share fell to its 52-week low of $4.94. The company has a valuation of $185.86M, with an average of 0.24 million shares in intraday trading volume over the past 10 days and average of 661.11K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Corbus Pharmaceuticals Holdings Inc (CRBP), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CRBP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.22.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) trade information
After registering a -0.26% downside in the last session, Corbus Pharmaceuticals Holdings Inc (CRBP) has traded red over the past five days. The 5-day price performance for the stock is -14.37%, and -19.30% over 30 days. With these gigs, the year-to-date price performance is 152.65%. Short interest in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) saw shorts transact 2.4 million shares and set a 6.46 days time to cover.
The extremes give us $35 and $82 for target low and target high price respectively. As such, CRBP has been trading -437.35% off suggested target high and -129.36% from its likely low.
Corbus Pharmaceuticals Holdings Inc (CRBP) estimates and forecasts
Looking at statistics comparing Corbus Pharmaceuticals Holdings Inc share performance against respective industry, we note that the company has outperformed competitors. Corbus Pharmaceuticals Holdings Inc (CRBP) shares are -65.42% down over the last 6 months, with its year-to-date growth rate higher than industry average at 58.97% against 16.60%.
CRBP Dividends
Corbus Pharmaceuticals Holdings Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s Major holders
Corbus Pharmaceuticals Holdings Inc insiders hold 0.75% of total outstanding shares, with institutional holders owning 105.26% of the shares at 106.06% float percentage. In total, 105.26% institutions holds shares in the company.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Corbus Pharmaceuticals Holdings Inc (CRBP) shares. Going by data provided on Sep 30, 2024, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 391.28 shares. This is just over 3.21% of the total shares, with a market valuation of $5.97 million. Data from the same date shows that the other fund manager holds a little less at 329.22, or 2.70% of the shares, all valued at about 5.02 million.
